Effect of body mass index on prostate volume and prostate-specific antigen in men over 50: A cross-sectional study

Abstract

Objectives:

To assess the relationship between body mass index (BMI) and prostatic-specific antigen (PSA) levels, and prostate volume (PV) in men over 50 years.

Methods:

This cross-sectional study was conducted at the Urology Outpatient Clinic at Badr Hospital and 15th May Hospital over a period of 6 months on 300 male patients over 50 years of age. The international prostate symptom score (IPSS) was used to evaluate the severity of lower tract urinary symptoms. Patients were classified according to their BMI as underweight, normal, overweight, obese, and very obese.

Results:

The patients’ mean age was 69.01 ± 11.95 years, and their mean BMI was 23.65 ± 3.54 kg/m². An increasing trend was observed between the studied groups in terms of PV and IPSS scores. Very obese patients were associated with a significant (p < 0.05) higher PV and IPSS, followed by obese, overweighted, normal weight, and underweighted patients. On the other hand, obese patients were associated with significantly (p = 0.005) lower PSA levels compared with individuals with normal or underweight. A significant positive correlation between BMI and PV and IPSS (r = 0.316, p < 0.001 and r = 0.36, p < 0.001), respectively. We found a significant negative correlation between BMI and PSA level (r = −0.33, p < 0.001).

Conclusion:

Among patients older than 50, a significant correlation between BMI and PV, PAS, and IPSS was found. Obese patients had significantly higher PV and IPSS scores, and lower PAS levels than normal weight patients. Further studies are required to investigate the relationship between obesity and LUTS and the predictors of developing BPH in elderly patients.

Keywords

Body mass index prostate-specific antigen prostate volume cross-sectional elderly

Get full access to this article

View all access options for this article.

References

Guh

Zhang

Bansback

, et al. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health 2009; 9: 88.

Faith

Butryn

Wadden

, et al. Evidence for prospective associations among depression and obesity in population-based studies. Obes Rev 2011; 12: e438–e453.

Zhao

Cheng

Wang

, et al. BMI and serum lipid parameters predict increasing risk and aggressive prostate cancer in Chinese people. Oncotarget 2017; 8: 66051–66060.

Demark-Wahnefried

Conaway

Robertson

, et al. Anthropometric risk factors for prostate cancer. Nutr Cancer 1997; 28: 302–307.

Berry

Coffey

Walsh

, et al. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474–479.

Patel

Parsons

JK.

Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction. Indian J Urol 2014; 30: 170–176.

Lee

Min

Choi

, et al. Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring) 2006; 14: 172–179.

Stamey

Yang

Hay

, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–916.

Oesterling

Chan

Epstein

, et al. Prostate specific antigen in the preoperative and postoperative evaluation of localized prostatic cancer treated with radical prostatectomy. J Urol 1988; 139: 766–772.

10.

Seo

Yoon

Choi

, et al. The correlation between body mass index and routine parameters in men over fifty. World J Mens Health 2017; 35: 178–185.

11.

Freedland

Wen

Wuerstle

, et al. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology 2008; 72: 1102–1105.

12.

Wright

Lin

Stanford

JL.

The effect of demographic and clinical factors on the relationship between BMI and PSA levels. Prostate 2011; 71: 1631–1637.

13.

Oesterling

JE.

Age-specific reference ranges for serum PSA. N Engl J Med 1996; 335: 345–346.

14.

Zhao

Chen

, et al. Relationship between metabolic syndrome and predictors for clinical benign prostatic hyperplasia progression and international prostate symptom score in patients with moderate to severe lower urinary tract symptoms. Urol J 2016; 13: 2717–2726.

15.

Kim

Doo

Yang

, et al. Effects of obesity on prostate volume and lower urinary tract symptoms in korean men. Korean J Urol 2010; 51: 344–347.

16.

Sanman

Shetty

Adapala

, et al. Can new, improvised visual prostate symptom score replace the international prostate symptom score? Indian perspective. Indian J Urol 2020; 36: 123–129.

17.

Mitterberger

Horninger

Aigner

, et al. Ultrasound of the prostate. Cancer Imaging 2010; 10: 40–48.

18.

Tyloch

Wieczorek

. The standards of an ultrasound examination of the prostate gland. Part 1. J Ultrason 2016; 16: 378–390.

19.

Dasan

Patil

Correlation of sonographic prostate volume with international prostate symptom score in South Indian men. Int J Res Med Sci 2015; 3: 3126–3130.

20.

Udeh

Dakum

Aderibigbe

, et al. The utility of digital rectal examination in estimating prostate volume in a rural hospital setting. Niger J Surg 2015; 21: 111–114.

21.

Lenaghan

Woo

HH.

Dichotomous estimation of prostate volume: a diagnostic study of the accuracy of the digital rectal examination. World J Mens Health 2013; 31: 220–225.

22.

Nickel

Méndez-Probst

Whelan

, et al. 2010 Update: guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J 2010; 4: 310–316.

23.

B-H

Deng

Huang

, et al. Body mass index and risk of prostate volume, international prostate symptom score, maximum urinary flow rate, and post-void residual in benign prostatic hyperplasia patients. Am J Mens Health 2019; 13: 1557988319870382.

24.

Yelsel

Alma

Eken

, et al. Effect of obesity on international prostate symptom score and prostate volume. Urol Ann 2015; 7: 371–374.

25.

Chen

Miao

Gao

, et al. Effect of obesity and hyperglycemia on benign prostatic hyperplasia in elderly patients with newly diagnosed type 2 diabetes. Int J Clin Exp Med 2015; 8: 11289–11294.

26.

Orakwe

Tijani

Jeje

, et al. Comparison of the pre-treatment testosterone levels in benign prostatic hyperplasia and prostate cancer patients. African J Urol 2017; 23: 105–108.

27.

Kim

Yang

Song

, et al. Correlation between prostate volume and metabolic or anthropometric factors in male visitors to a health promotion center. Korean J Urol 2008; 49: 139–144.

28.

Harrison

Tilling

Turner

, et al. Investigating the prostate specific antigen, body mass index and age relationship: is an age-BMI-adjusted PSA model clinically useful? Cancer Causes Control 2016; 27: 1465–1474.

29.

Baillargeon

Pollock

Kristal

, et al. The association of body mass index and prostate-specific antigen in a population-based study. Cancer 2005; 103: 1092–1095.

30.

Loeb

Carter

Schaeffer

, et al. Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore longitudinal study of aging. J Urol 2009; 182: 2646–2651.

31.

Grammatikopoulou

Gkiouras

Papageorgiou

SΤ

, et al. Dietary factors and supplements influencing prostate specific-antigen (PSA) concentrations in men with prostate cancer and increased cancer risk: an evidence analysis review based on randomized controlled trials. Nutrients 2020; 12: 2985.

32.

Tafuri

Rizzetto

Amigoni

, et al. Predictors of lymph node invasion in patients with clinically localized prostate cancer who undergo radical prostatectomy and extended pelvic lymph node dissection: the role of obesity. Urol Int 2021; 105: 362–369.

33.

Porcaro

Tafuri

Sebben

, et al. High body mass index predicts multiple prostate cancer lymph node metastases after radical prostatectomy and extended pelvic lymph node dissection. Asian J Androl 2020; 22: 323–329.

34.

Tafuri

Amigoni

Rizzetto

, et al. Obesity strongly predicts clinically undetected multiple lymph node metastases in intermediate- and high-risk prostate cancer patients who underwent robot assisted radical prostatectomy and extended lymph node dissection. Int Urol Nephrol 2020; 52: 2097–2105.

35.

Porcaro

Sebben

Tafuri

, et al. Body mass index is an independent predictor of Clavien-Dindo grade 3 complications in patients undergoing robot assisted radical prostatectomy with extensive pelvic lymph node dissection. J Robot Surg 2019; 13: 83–89.